.png)
Agenzia Italiana del Farmaco
EMA starts review of sickle cell disease medicine Oxbryta - EMA starts review of sickle cell disease medicine Oxbryta
EMA starts review of sickle cell disease medicine Oxbryta
Review follows reports of fatal cases in clinical trials.
EMA has started a review of Oxbryta (voxelotor) after data from a clinical trial showed that a higher number of deaths occurred with Oxbryta than with placebo (a dummy treatment) and another trial showed the total number of deaths was higher than anticipated.
Published on: 02 August 2024
